Search Results

The ColorPAC™ Toxin A test is indicated for the qualitative detection of Clostridium difficile toxin A (enterntaxin) in stool specimens from patients used for the seefing C. difficile associated disease. The test can also be used for the confirmation of suspect colonies of toxigenic C. difficile from agar plates or BHI broth. The assay is intended for use as an aid in the diagnosis of C. difficile associated disease. The test is not indicated for asymptomatic adults or children. This device is not indicated for use in a point of care setting.

The ColorPAC Toxin A test is comprised of a capture line consisting of C. difficile toxin A antibody immobilized on a chromatographic test strip which is contained within a test device. A specimen (stool, colonies, or BHI broth) is diluted with sample buffer and added to the sample well of the test device. The diluted sample wicks up the test strip by capillary action. Toxin A, if present, binds to the capture antibody at the test line as the specimen migrates across the test strip. The wash and remaining reagents are added to the reagent well of the test device. Upon addition of Detector A, toxin A antibody coated liposomes containing a pink dye migrate across the test strip and attach to the C. difficile toxin A antigen that was bound to the test strip in the previous step. Color formation is enhanced upon addition of a second liposome reagent, Detector B, that binds to the complex formed between Detector A and sample antigen at the test line. Following the final wash, the reactions are read visually. If toxin A antigen is detected in the patient specimen, a pink test line and a pink control line will appear, indicating a positive result. In the absence of toxin A, only the pink control line will appear, indicating a negative result. The result is uninterpretable if there is no pink control line or if the background obscures reading of the control line.

The ColorPAC™ Toxin A device is a rapid chromatographic assay for the qualitative detection of Clostridium difficile toxin A (enterotoxin) in stool specimens and for the confirmation of suspect colonies of toxigenic C. difficile. The performance data presented focuses on comparing the device to the Cytotoxin B assay.

Here's a breakdown of the acceptance criteria and the study details:

1. Acceptance Criteria and Reported Device Performance:

The document doesn't explicitly state "acceptance criteria" but presents performance metrics from the clinical studies. For comparison, we will use the results from the combined clinical study against the predicate device (Cytotoxin B assay) as the reported device performance.

2. Sample Size and Data Provenance for the Test Set:

• Sample Size: A total of 760 specimens were included in the combined clinical study for comparison with the Cytotoxin B assay (598 fresh and 162 frozen stool specimens).
• Data Provenance: The study was conducted at geographically diverse areas of the United States. The data appears to be retrospective as it involved testing specimens against an established routine assay (Cytotoxin B).

3. Number of Experts and Qualifications:

The document does not specify the number of experts used to establish the ground truth nor their qualifications. The ground truth for the clinical study was established by comparing the ColorPAC™ Toxin A assay to each site's routine Cytotoxin B assay.

4. Adjudication Method:

The document does not describe any specific adjudication method (such as 2+1, 3+1). The comparison was made against the "routine cytotoxin B assay" at each site.

5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study:

No MRMC study was mentioned in the provided text. The study design focused on comparing the ColorPAC™ Toxin A device against a predicate laboratory test (Cytotoxin B assay), not on human reader performance with or without AI assistance.

6. Standalone Performance:

Yes, the provided data reports the standalone performance of the ColorPAC™ Toxin A device against the Cytotoxin B assay. The sensitivity and specificity values listed above represent the performance of the device without human-in-the-loop assistance in interpreting the results once the test is run. The "read visually" step is inherent to the device's design, but the metrics are for the device's ability to detect the toxin.

7. Type of Ground Truth Used:

The ground truth for the clinical studies (comparing ColorPAC™ Toxin A to Cytotoxin B) was established by the Cytotoxin B assay. For the colony confirmation study, the "toxigenic status was determined by a cytotoxin B assay." This means the predicate device itself served as the reference standard for establishing the ground truth.

8. Sample Size for the Training Set:

The document does not provide details on a separate "training set" or its sample size. The performance data presented is likely derived from validation studies, with the clinical study representing a performance evaluation.

9. How the Ground Truth for the Training Set Was Established:

As no explicit "training set" is described, this information is not available. The development and validation of the ColorPAC™ Toxin A assay would have involved internal studies, likely using characterized samples, but these are not detailed as a distinct "training set" with ground truth establishment methods in this document.

Ask a specific question about this device